Drug Trial Radar · NCT06972264
Safety and Efficacy of VDPHL01 in Males With AGA
Last checked: Nov 19, 2026Latest source record: Feb 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
480
Planned (sponsor's estimate)
Start
Mar 11, 2025
Primary completion
Dec 2026
Study completion Jul 2027
Sponsor
- Lead sponsor
- Veradermics, Inc.Industry
- Sponsor type
- Industry
- First posted
- May 14, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the safety and efficacy of VDPHL01 in male subjects with Androgenetic Alopecia (AGA). AGA (or male pattern baldness) is a genetic disorder caused by an excessive (too much) hair follicle response to androgens (hormone) that causes hair loss. VDPHL01 8.5 mg Tablet is an investigational oral drug to treat male pattern baldness. This multi-center, double blind, study will last about 13 months and includes 11 study visits (screening, baseline (day 1), week 2, month 1, month 2, month 4, month 6, month 8, month 10, month 12, month 13).
Conditions
- Androgenetic Alopecia
- AGA
- Male Pattern Baldness
Interventions
VDPHL01Drug
VDPHL01 Extended Release (ER) Tablet
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Changes in non-vellus Target Area Hair Counts (TAHC)Time frame: Month 6
- Subjects Evaluation of Treatment BenefitTime frame: Month 6
Locations
44 sites in 1 country. Site status is shown where the registry gives one.
Site 73
Birmingham, Alabama
Site 89
Birmingham, Alabama
Site 77
Phoenix, Arizona
Site 69
Encino, California
Site 64
Manhattan Beach, California
Site 93
Northridge, California
Site 66
Santa Monica, California
Site 94
Thousand Oaks, California
Site 71
Boca Raton, Florida
Site 86
Coral Gables, Florida
Site 62
Coral Gables, Florida
Site 99
Miami, Florida
Site 54
Ocala, Florida
Site 96
Tamarac, Florida
Site 90
Sandy Springs, Georgia
Site 61
Chicago, Illinois
Site 53
Clarksville, Indiana
Site 55
Plainfield, Indiana
Site 79
Leawood, Kansas
Site 52
Louisville, Kentucky
Site 75
New Orleans, Louisiana
Site 84
Glenn Dale, Maryland
Site 87
Rockville, Maryland
Site 80
Chestnut Hill, Massachusetts
Site 59
Quincy, Massachusetts
Site 68
Clinton Township, Michigan
Site 83
Troy, Michigan
Site 82
Hickory, North Carolina
Site 92
Huntersville, North Carolina
Site 72
Cincinnati, Ohio
Site 57
Portland, Oregon
Site 81
East Greenwich, Rhode Island
Site 60
Anderson, South Carolina
Site 95
Hermitage, Tennessee
Site 76
Austin, Texas
Site 51
Austin, Texas
Site 74
College Station, Texas
Site 67
Dallas, Texas
Site 78
Plano, Texas
Site 88
San Antonio, Texas
Showing 40 of 44 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.